HAL (France)
open access
CFTR correctors potentiate gating mutants causing cystic fibrosis
The Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulator VX-445 (Elexacaftor) used to treat cystic fibrosis presents both corrector and potentiator activities. This drug binds to a pocket within the CFTR membrane-spanning domain (MSD) assembly, in contact with the lasso motif. We hav
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Editorial: Tailored Modulation of Interactions Between Biomolecules: Fundamentals and Applications#250622
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del -gating and F508del -residual function genotypes: results from an open-label extension study#971087
- Male reproductive phenotype in cystic fibrosis: comparison of existing animal models#1157770
- Surrogate antigens as targets for proteome-wide binder selection#452365
- Supplementary Material for: The small ubiquitin-like modifier SUMO-3 acts as a neutrophil chemoattractant via the chemokine receptors CXCR1 and CXCR2#382051
Record · ID 1399607
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive